Share on StockTwits
 

Genetic Technologies (NASDAQ:GENE) was upgraded by research analysts at Ladenburg Thalmann from a “neutral” rating to a “buy” rating in a report released on Thursday, TheFlyOnTheWall.com reports. The firm currently has a $2.50 target price on the stock. Ladenburg Thalmann’s price target points to a potential upside of 74.36% from the company’s current price.

Genetic Technologies (NASDAQ:GENE) traded up 54.55% during mid-day trading on Thursday, hitting $2.21. The stock had a trading volume of 5,740,529 shares. Genetic Technologies has a 52-week low of $1.30 and a 52-week high of $3.35. The stock has a 50-day moving average of $1.54 and a 200-day moving average of $1.95. The company’s market cap is $38.1 million.

Genetic Technologies Limited is engaged in a diagnostic product business. The Company translates genetic tests into products and services.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.